Tag: LRRK2
A drug to lower activity of the protein LRRK2 — which is higher in some people with Parkinson’s — will move into a later-stage trial this year a...
The Michael J. Fox Foundation (MJFF) plays a critical role in convening partners and competitors to work together on new treatments and disease measur...
Increased caffeine intake is linked to a decreased risk of Parkinson’s disease (PD) in people who have a LRRK2 genetic mutation, which is associated...
Recent findings suggest LRRK2 kinase inhibitors—a type of Parkinson’s drug now being tested in clinical trials—may benefit a broad array of pati...
“Forbes” recently published a story detailing a “milestone moment” in the history of LRRK2 and the linchpin role of The Michae...
Denali Therapeutics has announced positive results from its first-in-human LRRK2 inhibitor clinical trial. The trial concluded that the experimental t...
Parkinson’s is a variable disease — different in age of onset, experience of symptoms and cause — but a new study points to a potential common l...
Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently an...
Today we share the research of Professor Glenda Halliday and Dr Nicholas Dzamko and the world leading LKK2 research they are conducting at The Univers...